Is Additional Endocrine Therapy Likely to Reduce Her Risk?
Cancer
Index
Prognostic ≠ Predictive
In determining whether extended endocrine therapy is right for your early-stage, hormone receptor–positive (HR+) breast cancer patient, understanding her risk of recurrence is an important consideration.
Knowing whether the treatment is likely to benefit her is crucial.
What are Prognostic vs. Predictive factors?
Predictive
Factors:
Factors:
- Assess the most likely response to a particular treatment
- May help determine whether a patient is likely to benefit from treatment
Prognostic
Factors:
Factors:
- Evaluate the progression of a disease, with or without treatment
- May help determine a patient’s risk of recurrence
Clinical and Pathologic Factors Do Not Reliably Predict Benefit From Extended Endocrine Therapy
While clinicopathologic factors may help in the prognostic evaluation of recurrence risk, these factors and other commercially available tests have not been validated to predict benefit from extended endocrine therapy1-4
Tumor size
Tumor grade
RS + quantitative ER
Menopausal status
KI67
Age
Other genomic assays
BCI Is THE ONLY Commercially Available Test That Can Predict Whether Another 5 Years Of Endocrine Therapy Is Likely To Help Reduce Her Risk Of Late-Distant Recurrence.
Learn More About the Predictive Power of BCIReferences: 1. Davies C et al., Lancet. 2013 ;381(9869):805-16. 2. Goss PE et al, J Natl Cancer Inst 2005;97:1262–71. 3. Goss PE et al., N Engl J Med. 2016 Jun 5 (Online). 4. Mamounas EP et al. San Antonio Breast Cancer Symposium, 2016.
Back To AllBack to Top
